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Twenty-nine years into the HIV epidemic, several advances have been made; however, there remain several challenges particularly
with pediatric HIV in resource-limited countries. The obstacles facing pediatric antiretroviral therapy (ART) delivery in resource-
limited countries are multifaceted: lack of health care infrastructure, limited availability of pediatric drug formulations, lack of
early HIV diagnostic and monitoring techniques, limited manpower with expertise in pediatric HIV care, limited donor funding,
and competing public health priorities with limited health care budget. In this paper, the challenges with various ART monitoring
tools in resource-limited countries are discussed. Noninvasive (e.g., patient, clinical events outcome, and adherence) and invasive
(e.g., immunologic and virologic) monitoring tools are discussed. Several cheap and technically less complex laboratory tests
for monitoring are becoming available. Funding agencies and country programs should invest in validating the use of current
technologies to optimize pediatric HIV care in resource-limited countries.
1.Introduction
The current state of the HIV epidemic can be likened to
the description of the setting of Charles Dickens’s novel,
“A Tale of Two Cities”—“it was the best of times, it was
the worst of times, it was the age of wisdom, it was
the age of foolishness, it was the epoch of belief, it was
the epoch of incredulity...” Twenty-nine years into the
HIV epidemic, several advances have been made; however,
there remain several challenges with regard to access and
management of antiretroviral therapy (ART), particularly
in resource-limited countries. While the birth of an HIV-
infected child is rare in resource-rich countries, mother-
to-child transmission (MTCT) of HIV continues to fuel
the HIV epidemic in resource-limited countries [1]. Two
sentinel advances in the pediatric HIV epidemic were (1) an
initial 67% reduction in perinatal HIV transmission with the
administration of zidovudine (AZT) during pregnancy and
peripartum period [2]a n d( 2 )as u b s e q u e n tr e d u c t i o no f
perinatal transmission of HIV by 98%-99% in resource-rich
countries with the use of highly active antiretroviral therapy
(HAART) during pregnancy [3]. Despite these successes,
progress has not been uniform worldwide and care for
HIV-infected children continues to lag behind. About 2
million of the 2.1 million HIV-infected children live in
sub-Saharan Africa, where there is still limited access to
antiretroviral drugs even with the unprecedented global
eﬀortatscalingupART[4].About1000childrenareinfected
with HIV each day worldwide. At the end of December
2008, only 38% of HIV-infected children less than 15 years
of age in resource-limited countries needing ART were on
therapy(Table 1)(http://www.who.int/hiv/topics/paediatric/
data/en/index.html). The disparity in global coverage of
ART, as illustrated in Table 1, underscores the need to scale
up pediatric ART delivery. The obstacles facing pediatric
ART delivery in resource-limited countries are multifaceted:
lack of health care infrastructure, limited availability of
pediatricdrugformulations,lackofearlyHIVdiagnosticand
monitoring techniques, limited manpower with expertise in
pediatric HIV care, limited donor funding, and competing
public health priorities with limited health care budget [5–
7].
ThehallmarkofHIVinfectionisprogressiveCD4+Tcell
depletion leading to an increased risk for the development
of opportunistic infections, acquired immune deﬁciency
syndrome (AIDS), and death [8–10]. The advent of HAART2 AIDS Research and Treatment
Table 1: Antiretroviral therapy coverage among HIV-infected children less than 15 years of age in resource-limited countries, December
2008.
Geographical region Number on ART Number needing ART (range) Percent of coverage (range) Percent of total need
Eastern and Southern Africa 195100 440000 (340000–540000) 44% (36%–57%) 61%
Western and Central Africa 29800 200000 (140000–260000) 15% (11%–22%) 27%
Latin America 13700 17000 (14000–20000) 82% (70%– >95%) 2%
The Caribbean 2500 4600 (3400–5800) 55% (43%–72%) 1%
East, South, and South-East Asia 30000 58000 (41000–78000) 52% (38%–73%) 8%
Europe and Central Asia 4200 4900 (2700–7500) 85% (56%– >95%) 1%
North Africa and the Middle East 400 6700 (3400–11000) 6% (4%–12%) 1%
Total 275700 730000 (580 000–880 000) 38% (31%–47%) 100%
Adapted from (http://www.who.int/hiv/topics/paediatric/data/en/index.html).
in 1996 signiﬁcantly reduced the morbidity and mortality
in HIV-infected children in both resource-rich countries
[11, 12] and resource-limited countries [13–17]. However,
thetreatmentofHIVinfectionisalife-longundertaking,and
therapeutic beneﬁt can be limited by the evolution of drug-
resistant virus and long-term toxicity resulting in treatment
failure [18, 19]. There is the need to monitor treatment to
earlydetectandavoidtheuntowardeﬀectsofHAART.Inthis
paper,thesuccessesatmonitoringantiretroviraltreatmentin
HIV-infected children in resource-limited countries and the
challenges that remain are discussed.
2.Monitoringthe Response to
AntiretroviralTherapy
The goal of HAART is to suppress HIV viral replication
and restore immune function. Successful treatment results
in virologic suppression, a quantitative increase in the
number of CD4+ T cells, and improvement in the clinical
well-being of the individual, manifesting as weight gain
and resolution or control of opportunistic infections. In
resource-limited countries, the World Health Organization
(WHO) recommends initiating ART for (i) HIV-infected
infants diagnosed in the ﬁrst year of life, irrespective of
CD4 count or WHO clinical stage, (ii) HIV-infected children
between 12 and 24 months of age irrespective of CD4+
T cell count or WHO clinical stage, (iii) HIV-infected
children between 24 and 59 months of age with CD4+ T
cell count of ≤750cells/mm3 or %CD4+ ≤25, whichever is
lower, irrespective of WHO clinical stage, (iv) HIV-infected
childrenmorethan5yearsofagewithaCD4+Tcellcountof
≤350cells/mm3 (as in adults), irrespective of WHO clinical
stage, (v) HIV-infected children with WHO clinical stages
3 and 4, irrespective of CD4 count, and (vi) any child less
than 18 months of age who has been given a presumptive
clinical diagnosis of HIV infection [20]. Despite the limited
armamentariumofﬁrst-lineantiretroviraldrugsinresource-
limited countries, national HIV/AIDS programs continue to
reportgoodtreatmentoutcomessimilartothoseinresource-
richcountries—with1and2yearsurvivalestimatedat93%–
95% and 91%, respectively [14, 15, 21–25]. In resource-rich
countries, the standard of care for monitoring treatment in
HIV-infected children is the routine laboratory monitoring
of CD4+ T cell percentage or count and HIV viral load [26].
In USA, CD4+ T cell percentage or count and HIV viral load
are measured at the time of diagnosis of HIV infection and at
least every 3-4 months thereafter (http://AIDSinfo.nih.gov/).
Due to the lack of accessible and aﬀordable laboratory ser-
vices,thesetestsarenotroutinelyavailableinmanyresource-
limitedsettings[27].TheWHOhighlyrecommendsnational
programs to develop the laboratory capacity for monitoring
ART. However, in the absence of laboratory capacity, clinical
parameters are used for monitoring ART. In this paper, the
challenges associated with various ART monitoring tools
in resource-limited countries are discussed. Noninvasive
(e.g., patient, clinical events outcome, and adherence) and
invasive (e.g., immunologic and virologic) monitoring tools
are discussed.
2.1. Patient Monitoring of Antiretroviral Therapy. Direct
patient monitoring is the most aﬀordable and cost-eﬀective
measure and forms the backbone of clinical care, treat-
ment, and prevention. The WHO has published technical
guidelines outlining ART care of infants and children to
guide health care delivery programs in resource-limited
countries [20]. These guidelines provide a list of essential
minimum standards of HIV care and ART monitoring
data to be collected at each clinic visit. The collection,
collation, and analysis of data on patients over time will be
useful for evaluation of both local and national programs.
Standardization of the data collection process will also make
it easy to identify strengths and weaknesses of programs.
An overarching advantage will be the ease of forming ART
care coalitions in resource-limited countries to inform best
practices parallel to lessons learned from the Pediatric AIDS
Clinical Trials Group (PACTG) in resource-rich countries.
Good record keeping continues to be a perennial prob-
lem in most resource-limited countries. Many health care
providers are not proﬁcient in basic data management skills,
and the few who are proﬁcient in data management are
overloadedwithworksuchthatdatamanagementisnottheir
priority. There is a need for national programs to invest in
training data management personnel to assist the providers
in collecting, storing, and analyzing data.AIDS Research and Treatment 3
2.1.1. Clinical Events Monitoring of Antiretroviral Therapy.
Clinical events monitoring provides a noninvasive and low-
cost measure for following patients on HAART. Since the
ultimate goal of HAART is to restore immune function
and halt HIV disease progression, the presence or absence
of certain clinical events can be used as surrogates for
monitoring the eﬃcacy of HAART. Children starting ART
in resource-limited countries are usually severely immuno-
compromised and very sick [22–25]. The immediate clinical
beneﬁt from ART initiation is improvement in the overall
well-being and functional status of the patient; subjective
and objective measures of these at follow-up visits can be
employed to monitor treatment success. Screening questions
such as (i) has the patient returned to school or play or
is the patient able to engage in activities of daily living
without help? (ii) Is the patient ambulating or bedridden?
An improvement score could be devised as a quick and
subjective assessment of improvement or “return of energy”
since starting ART. Using a scale of one to 10, with 10 being
“most improvement” and “return of energy” since starting
ART, the patient could be asked to score his/her state of
health. The answers to these questions will provide a quick
measureoftheeﬃcacyofART.However,providershavetobe
aware of the presenting symptoms of immune reconstitution
inﬂammatory syndrome (IRIS) in their patient cohort as
these could confound the functional state assessment [28]. A
semiquantitativeapproachtotheclinicalassessmentthatone
canexploreistousechangesinWHOclinicalstagingatclinic
visits after initiating ART. Studies are needed to determine
how long it takes for one to move to the next higher clinical
stage after initiating ART and to determine if these changes
will accurately predict virologic outcome.
The majority of children starting ART in resource-
limited countries have growth deﬁciencies. Growth failure
in HIV-infected children is a multifaceted problem; it is
partlydue to the underlying HIVinfection itself, withits lack
of virologic and immunologic control prior to ART, HIV-
associated opportunistic infections, and food deprivation
resulting from poverty. Several studies have demonstrated
weight gain in children after initiating ART [29, 30]. On
average,the weight gain is about 1.8–3.6kg in the ﬁrst yearof
ART.Themeanweight-for-agezscoresalsoincreasesubstan-
tially,byabout1SDfrom −2SDorbelowatbaseline[21,31–
34]. In a study of 212 HIV-infected children initiating ART,
they continued to catchup in growth and height through the
ﬁrst ﬁve years on ART [35]. In these studies, weight gain was
signiﬁcantly associated with virologic control. Where viral
load determinations are not feasible, weight gain could be
used as part of an algorithm to predict virologic responders.
Clinical algorithms based on signs, symptoms, and
simple laboratory assays are being used to identify and treat
patients needing ART in resource-limited countries [36, 37].
The Pediatric AIDS Clinical Trials Group (PACTG) 219
Study Team developed and validated a simple Pediatric AIDS
Severity Score (PASS) based on baseline weight percentile,
WHO clinical stage, symptoms, a general health rating, total
lymphocyte count, packed cell volume (hematocrit), and
a measure of albumin to guide decisions on initiation of
ART in resource-limited countries [38] .T h eP A S Ss y s t e m
provided a statistically signiﬁcant alternative to CD4+ T cell
percent and HIV viral load in deciding when to start ART
[38]. Such a measure could be adapted in resource-limited
countries. Other clinical indices that could provide easy
measure of treatment outcome are resolution or decreased
frequency or reduction in the severity of HIV-associated
illnesses. It has been shown that the incidence of diar-
rheal diseases, pneumonia, and hospitalization among HIV-
infected children decreases substantially on ART [13, 14, 39].
2.1.2. Adherence Monitoring of Antiretroviral Therapy.
Adherence to treatment regimens is a prerequisite for the
eﬃcacy and durability of any antiretroviral therapy regimens
[40, 41]. In resource-limited countries, where second-line
regimens are limited, keeping a patient on a ﬁrst-line regi-
men as long as possible is an important goal of ART. Patients
starting ART should, therefore, be counseled on the need
for adherence, and adherence should be monitored at every
encounter with the patient. Several studies from resource-
limited countries have reported prevalence of adherence
among HIV-infected children similar or better than that
achieved among those in resource-rich countries [25, 39, 42–
45]. There are several measures of adherence, for example,
self-report or sophisticated microelectronic monitors that
record bottle openings and reconstruct complex pill-taking
patterns [46, 47]. Due to resource constraints, self-reporting
adherence is used predominantly in resource-limited coun-
tries.
One study compared the relative performance of various
low-cost adherence measures: caregiver recall, pill counts
at scheduled visits, and unannounced pill counts at home
visits. The proportion of patients who achieved perfect
adherence (i.e., >95%) was 72%, 89%, and 94% when
measured by unannounced pill count, caregiver report,
and pill count at scheduled visits, respectively [45]. In a
study from South Africa, investigators sought to determine
the accuracy of adherence assessments for predicting and
detecting virologic failure and to compare the accuracy of
adherence-based monitoring with CD4+ T cell monitoring
in HIV-infected adults on ART [48]. Pharmacy-based time-
to-reﬁll of HAART was used as a measure of adherence
[49]. Adherence was calculated as the number of months
for which ART claims were submitted to the pharmacy,
divided by the number of complete months from ART
initiation to the date of study endpoint, and the results
multiplied by 100. Adherence values were found to provide
statisticallysigniﬁcantaccuracyfordetectingvirologicfailure
at 6 and 12 months compared to CD4+ T cell count
changes (AUCs of 0.79 versus 0.68 at 6 months and 0.85
versus 0.75 at 12 months) [48]. This ﬁnding implies that
in resource-limited countries where CD4+ T cell counts
are not readily available, a comprehensive monitoring of
pharmacy reﬁll data could be used to identify patients
with a high probability of virologic failure. Grossberg et
al. determined the validity and utility of pharmacy-based
time-to-reﬁll measure of antiretroviral therapy adherence
in a cohort of 110 HIV-infected adults [49]. The viral
load of study individuals decreased by 0.12logcopies/mL4 AIDS Research and Treatment
(95% conﬁdence interval [CI] 0.01–0.23logcopies/mL) for
each 10% increase in pharmacy-based time-to-reﬁll deﬁned
adherence as compared with 0.05logcopies/mL (95% CI:
−0.14–0.25logcopies/mL) for the self-reported adherence
measure. The key to the validity of using adherence measures
as surrogates for monitoring depends on meticulous acqui-
sition, maintenance, collation, and analysis of the data and
making pharmacy data available at each patient encounter.
Country programs will have to devise a comprehensive and
an easy-to-access pharmacy medication reﬁll database.
Though the importance of adherence is universally rec-
ognized,thereisnoconsensusonhowtomeasureadherence.
S e v e r a lp r o g r a m sh a v ea d o p t e da d h e r e n c em e a s u r e sb a s e d
on availability of resources. For example, in Malawi, patients
are given a 30-day supply of 60 antiretroviral (ARV) pills,
and a pill count is carried out at each visit (every 28 days),
and patient adherence is said to be >95% if a patient has
eight pills or fewer at each visit [41]. Columbia University’s
MTCT-plus program sites use a 7-day patient recall of num-
ber of pills taken, and adherence is categorized according
to response as none, very few, about half, most, and all of
the pills [20]. The WHO provides a guide for estimating
adherence: adherence is said to be “good adherence” (i.e.,
missing ≤3 doses in a month, ≥95%), “fair adherence”
(i.e., missing 4–8 doses in a month, 85%–94%), and “poor
adherence” (i.e., missing ≥9 doses in a month, <85%) [20].
It is therefore feasible for all programs to measure adherence
as a surrogate of treatment outcome. The irony is that the
bestmeasureofadherenceisvirologicassessment.Therefore,
funding agencies and country programs should strive to
institute viral load measurement as part of all HIV care
programs.
2.2. Immunologic Monitoring of Antiretroviral Therapy.
CD4+ T cell count remains the single most important
parameter in monitoring ART in HIV-infected individuals
[26, 50–52]. CD4+ T cell monitoring is more appropriate
than virologic monitoring because a decreasing CD4+ T cell
countisabetterpredictorofdiseaseprogression[53].Table 2
illustrates the immunologic and virologic outcomes of
antiretroviral therapy in HIV-infected children in resource-
limited countries obtained from selected papers published in
thelast5years[22–25,54–57].Theimmunologicoutcomeof
ART in HIV-infected children in resource-limited countries
is comparable to that of children in resource-rich countries.
However, due to resource constraints and technological
challenges, CD4+ T cell count determination is still not
available in all HIV care programs in resource-limited
countries, and, where available, frequent determinations are
not feasible as illustrated by several missing data points in
Table 2. In these studies, on average the children doubled
theirbaseline CD4+ T cellcountaftersix months ontherapy.
The CD4+ T cell count continued to increase at the same
rate over the second 6 months and slowed thereafter. The
gain in CD4+ T cell count at 18 months on therapy was
not very diﬀerent from that at 12 months. In the Zambian
study, where CD4+ T cell values were available for some of
the patients at 24 months, there was no signiﬁcant increase
between the 12- and 24- month CD4+ T cell values [24].
Studies of HIV-infected adults have shown that CD4+ T cell
recoveryreachesaplateauafter4to5yearsofHAARTdespite
completeviralsuppression[58–60].Couldwetakeadvantage
of this observation to determine when and how often to
monitor CD4+ T cell counts in HIV-infected children on
ART in resource-limited countries?
Because of the well-known large natural decline and
v a r i a t i o ni na b s o l u t eC D 4 +Tc e l ln u m b e r si ne a r l yc h i l d -
hood [63, 64], the percentage of CD4+ T cell is used for
monitoring HIV disease progression in children particularly
in those less than 5 years of age [65]. As shown in Table 2,
it is interesting to note that the changes in the percentage of
CD4+ T cells with treatment are similar to that of absolute
CD4+ T cell count. This is consistent with our recent ﬁnding
that absolute CD4+ T cell count had similar utility as CD4+
T cell percentage in monitoring HIV infection in a pediatric
cohort in the US, regardless of age [66]. Others have found
that absolute CD4+ T cell counts have less prognostic value
in younger children than CD4+ T cell percentage [67]. In
resource-limitedcountries,mostlow-costassaysavailablefor
enumeration of CD4+ T cells mainly provide the absolute
counts but not the percentages [27]. There is a need for
further studies to examine whether absolute CD4+ T cell
counts could be used for children of all ages, especially in
situations where available instruments provide only absolute
CD4+ T cell counts.
2.3. Virologic Monitoring of Antiretroviral Therapy. HIV viral
load is a useful tool for initiation and monitoring of ART
[51]. It is not a part of the WHO recommendation for
routine monitoring of ART in resource-limited countries.
HIV-infected children are less likely than infected adults to
achieve full viral suppression on ART [68–70]. The cut-
oﬀ for undetectable viral load diﬀers among studies from
resource-limited countries (Table 2); however, the propor-
tion of patients who achieved virologic success is comparable
to that in resource-rich countries. Only six of the studies had
a viral load for at least two time points. This is most likely
due to the cost and the need for sophisticated equipment
for determination of viral load. Viral load is a valuable tool
for detecting early treatment failure, and it is all the more
important in resource-limited countries where second-line
regimens are limited. For HIV-infected individuals on ART,
it has been found that the CD4+ T cell count and viral
load after six months of ART are the strongest predictors of
disease progression and death [71, 72]. In resource-limited
countries, perhaps viral load determination could also be
done less frequently. The critical assay could be the one per-
formed at six months of ART, and the frequency of testing,
thereafter, would depend on accessibility, aﬀordability, and
the clinical condition of patient.
3. Future of Laboratory Monitoring of
AntiretroviralTherapy:TheAgeofWisdom
Immunologic and virologic measures are the state of the art
for monitoring antiretroviral therapy and should be madeAIDS Research and Treatment 5
Table 2: Immunologic and virologic outcomes of antiretroviral therapy in HIV-infected children in resource-limited countries.
S t u d y 1234 5 67 89 1 0 1 1
Average
of all
studies
Number of children 2928 67 151 29 107 212 285 274 67 250 78 —
Country [ref]∗ Zambia
[24]
India
[57]
South
Africa
[25]
Kenya
[54]
Thailand
[55]
Cambodia
[23]
Haiti
[22]
Thailand
[56]
Kenya
[39]
Uganda
[61]
Cote
d’Ivoire
[62]
—
Median age (years) 6.75 6.28 5.3 8.5 7.7 6 6.3 7 4.4 9.2 6.5 6.7
WHO clinical staging
III or IV (%) 72.4 49.3 70.2 62.1 72 64.5 98 65 82 89 na 72.5
Median CD4 count at
baseline (cells/mm3) 284 225 na 182.3 72 100 608 na 288 272 na 253.9
CD4 gain at 6 months 280 478 na 203 226 na na na 210 na na 279.4
CD4 gain at 12 months 351 516 na 334 332 490 na na na na na 404.6
CD4 gain at 18¶ or 24
months 427¶ 493¶ na na 532 na na na na na na 460¶
Median CD4% at
baseline 12.9 12 7.4 na 3 6 12 5 5.8 8.6 7.5 8.02
CD4% gain at 6 months 10.8 8 10.2 na 12 na na 7 9.4 na 4.6 8.86
CD4% gain at 12
months 14.1 11 16.2 na 17 17 10.3 na na na 11.1 13.8
CD4% gain at 18¶ or 24
months 15.1¶ 13¶ na na 21 na na 18 na na 16 19.5
Median viral load (VL)
at baseline (Log) na na na 5.11 5.4 na 5.3 na 6.1 5.3 5.37 5.43
Proportion with
undetectable VL at 6
months (%)
na na 84 ∼50 53 na na na 67 na 52.1 61.2
Proportion with
undetectable VL at 12
months (%)
na na 80.3 na 69 81 56 na na 74 49.3 68.26
Proportion with
undetectable VL at 18
months (%)
na na na na 76 na na na na na 47.5 61.75
Frequency of CD4
determination
(months)
6 3–6 6 3 6 6 6 na 3–6 3–6 6 —
∗Reference to papers from which ﬁgures were extracted.
¶Values available at 18 months.
na: not available.
available in all settings where HIV infection is treated. With
the current ARV scale-up campaign, there is an unprece-
dented call on scientists to develop simpler, more robust,
low-maintenance, and cost-eﬃcient laboratory technologies
for monitoring antiretroviral therapy in resource-limited
countries. Posterity will not forgive modern science if it does
notdeliveritspromisetohelpmankindinitsdireneeds[73].
Moreover, the global community sees this as a moral duty,
leading to an unusual public-private sector partnership in
encouragingandfundingthenextgenerationofinnovations.
3.1. CD4+ T-Cell Testing. HIV primarily targets CD4+ T
cells, and CD4+ T cells play an essential role in HIV
pathogenesis [74]. Gut-associated lymphoid tissue (GALT)
contains about 60% of the body’s total CD4+ T cell
pool, and it is an important site of HIV viral replication
during acute HIV infection leading to signiﬁcant CD4+
T cell depletion [75]. Chronic HIV infection aﬀects both
quantitative and qualitative function of CD4+ T cells. CD4+
T cell recovery during ART is biphasic: an increase of
about 100–200cells/mm3 during the ﬁrst year of virologic
suppression on ART, followed by a gradual increase [76].
Given the central role of CD4+ T cells in HIV pathogenesis,
CD4+ T cell determination during the course of HIV disease
is one of the most reliable predictors of prognosis [26].
Despite the global eﬀort to make CD4+ T cell deter-
mination available in all HIV treatment centers, there are6 AIDS Research and Treatment
still quite a number of centers in resource-limited countries
with no access to reliable CD4+ T cell enumeration. The
challenge has been to develop a technology easy to operate,
able to withstand the tropical environment that could be
hostile to equipments, compatible with intermittent electric
power delivery, and aﬀordable [77]. Several relatively cheap
and technically less complex devices have been developed for
CD4+ T cell testing. These include the FACScount system
(Becton Dickinson Sciences, California), the Guava Easy
CD4 Assay (Guava technologies, Hayward California), the
Cyﬂow (Partec, Germany), and the panleucogating (PGL)
CD4 technique [78].
Many programs in resource-limited countries are using
these aﬀordable technologies; however, not all the devices
are designed for pediatric HIV management as they do not
measure the percentage of CD4+ T cells. The percentage of
CD4+ T cells, rather than the absolute number, has been
used as a marker of HIV disease progression in children [65].
This is due to the natural decline and variation in absolute
CD4+ T cell numbers in early childhood [63, 64]. There
are limited data on the long-term utility of the absolute
CD4+ T cell counts to guide treatment changes in pediatric
HIV. We recently reported that absolute CD4+ T cell count
had similar utility as CD4+ T cell percentage in monitoring
HIV infection in a pediatric cohort in USA, regardless of
age [66] .T h e r ei san e e df o rf u r t h e rr e s e a r c ht od e t e r m i n e
whether absolute CD4+ T cell count can be used in place of
CD4+ T cells percentage in managing HIV-infected children
of all ages especially in areas where available CD4+ T cell
enumeration devices do not measure the CD4+ T cells
percentage.
3.2. Viral Load Testing. Viral load testing that has been
shown to optimize HIV care in resource-rich countries is
currently unavailable in most resource-limited countries.
HIV RNA assays used in resource-rich countries—Abbott
m2000 test, the Roche COBAS Taqman test, bioM´ erieux
NucliSens HIV-1 QT Assay, and Versant HIV-1 RNA 3.0
Assay (bDNA)—are not accessible in resource-limited coun-
tries due to costly technical equipment, complex technology,
expensive reagents, poor laboratory infrastructure, and pro-
hibitive maintenance cost. Unfortunately, the available com-
mercialassaysforviralloaddeterminationareveryexpensive
(between $50 and $100 per test) making it unaﬀordable to
manycentersinresource-limitedcountries[79].CD4+Tcell
count may be insensitive for detecting early treatment failure
asCD4+Tcellsmaytakeseveralmonthstodropsigniﬁcantly
after virologic failure. Moreover, there are instances of
discordant virology and immunologic responses, that is,
persistently low or declining CD4+ T cell counts despite
complete virologic suppression, or increasing CD4+ T cell
count during increasing viremia. Viral load determination
is therefore an essential complementary test to CD4+ T cell
count [80].
There are several cheaper viral load assays being devel-
oped and evaluated for use in resource-limited coun-
tries. Examples of these assays are the ultrasensitive p24
assay (a signal-ampliﬁcation boosted ELISA for HIV-1
p24 antigen in plasma after heat-mediated immune com-
plex dissociation), the ExaVir Load reverse transcrip-
tase activity test (an assay that quantify virion-associated
reverse transcriptase enzyme), “home-made” real-time
PCR HIV-1 RNA assays, the Liat HIV RNA analyzer
(http://www.iquum.com/products/analyzer.shtml), and the
SAMBA assay (http://www.haem.cam.ac.uk/ddu/). The per-
formances of these assays in comparison to assays used in
resource-rich settings have received mixed reviews [81, 82].
Eﬀorts are being made to optimize these assays to improve
their sensitivities and speciﬁcities. Even when these assays
are validated for clinical use, not all HIV clinics will be able
to access them locally as resources vary signiﬁcantly within
countries. To make testing available to all clinics, issues
surrounding specimen collection, processing, and transport
have to be taken into consideration. The use of dried blood
spots may be an ideal alternative for specimen collection in
rural settings, where there are no laboratories, as it can be
transported to testing sites at ambient temperature [81].
3.3.WhatDoWeDointheInterim? Therearepreponderance
of evidence to suggest that the use of CD4+ T cell enu-
meration and viral load determination in resource-limited
countries is the way to go as the use of clinical algorithms
are confounded by the protean of infections and diseases
that can masquerade as HIV- or AIDS-associated conditions.
The arguments against their routine use are sustained more
by consideration of cost, technical expertise, and lack of
infrastructure [78]. Country programs should make the
eﬀort to adopt available low-cost technologies in clinical
care of HIV patients. A question that remains unanswered
is: that is it necessary to have frequent determination of
CD4+ T cells and viral load as the practice in resource-
rich countries is currently? From the data reviewed herein
(Table 2), there is little if anything to be gained in measuring
CD4+ T cells and viral load more frequently than every 6–12
months. There is a need to come out with appropriate testing
intervals which will reduce the overall cost in managing a
patient and at the same time sensitive enough to capture
patients most likely to fail treatment. Research is needed to
investigate and validate monitoring algorithms that utilize
all the available tools, that is, more frequent noninvasive
measures and invasive measures in a timely and informed
fashion.
4. Conclusion
Great times and innovative technologies are on the horizon
for HIV care, particularly for pediatric HIV care in resource-
limited countries. The goal is not to abandon the tried and
tested monitoring modalities such as CD4+ T cell count
and viral load determinations but to develop technologies
that will make these aﬀordable, accessible, and acceptable
in resource-limited countries. Funding agencies and country
programs should invest in validating the use of current
technologies to optimize pediatric HIV care in resource-
limited countries.AIDS Research and Treatment 7
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